Overview

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

Status:
Active, not recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

Summary

This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.

Phase:

Phase 2

Details

Lead Sponsor:

Gemini Therapeutics, Inc.